Accelerating biomarker-guided drug development with Precision For Medicine


The integration of biomarkers into the drug development process is an area of growing interest. In this interview we speak with Gerald Messerschmidt and Deborah Phippard from Precision for Medicine (USA) about the biomarker capabilities of Precision for Medicine as well as how integrating biomarkers with clinical trials can aid precise patient and medication selection.

This content is sponsored by Precision for Medicine.